Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Nov
09
Today In Oncology
Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds
OptiTROP-Lung06 A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?
Ponatinib/Blinatumomab Improves Event-Free Survival in Ph-Positive ALL
American Lung Association and Prevent Cancer Foundation Host Virtual QIW Workshop: Advancing Routine Clinical Use of Health Information From Chest CT Screening for Public Health
Izalontamab Brengitecan Improves Progression-Free Survival in EGFR-Mutated Advanced Nonsquamous NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo